|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600118062 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-02 08:11:55 |
|
注册时间: Date of Registration: |
2026-02-02 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
消化系统恶性肿瘤患者全疾病周期13个核心症状预测模型的构建与应用 |
|
Public title: |
Development and Application of a Predictive Model for 13 Core Symptoms Across the Entire Disease Trajectory in Patients with Digestive System Malignancies |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
消化系统恶性肿瘤患者全疾病周期13个核心症状预测模型的构建与应用 |
|
Scientific title: |
Development and Application of a Predictive Model for 13 Core Symptoms Across the Entire Disease Trajectory in Patients with Digestive System Malignancies |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
年芳 |
研究负责人: |
年芳 |
|
Applicant: |
Nian Fang |
Study leader: |
Nian Fang |
|
申请注册联系人电话: Applicant telephone: |
+86 183 8712 2587 |
研究负责人电话:
Study leader's |
+86 183 8712 2587 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
443960746@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
443960746@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国云南省昭通市昭阳区凤凰街道鲁甸路619号 |
研究负责人通讯地址: |
中国云南省昭通市昭阳区凤凰街道鲁甸路619号 |
|
Applicant address: |
No. 619 Ludian Road, Fenghuang Subdistrict, Zhaoyang District, Zhaotong, Yunnan, China |
Study leader's address: |
No. 619 Ludian Road, Fenghuang Subdistrict, Zhaoyang District, Zhaotong, Yunnan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
657000 |
研究负责人邮政编码: Study leader's postcode: |
657000 |
|
申请人所在单位: |
云南省滇东北中心医院 |
||
|
Applicant's institution: |
Northeast YunNan Central Hospital |
||
|
研究负责人所在单位: |
云南省滇东北中心医院 |
||
|
Affiliation of the Leader: |
Northeast YunNan Central Hospital, |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
kj2026003 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
云南省滇东北中心医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Northeast Yunnan Central Hospital, Yunnan Province |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-19 00:00:00 | ||
|
伦理委员会联系人: |
唐修柏 |
||
|
Contact Name of the ethic committee: |
Tang Xiubai |
||
|
伦理委员会联系地址: |
中国云南省昭通市昭阳区凤凰街道鲁甸路619号 |
||
|
Contact Address of the ethic committee: |
No. 619 Ludian Road, Fenghuang Subdistrict, Zhaoyang District, Zhaotong, Yunnan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 173 8708 2782 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
云南省滇东北中心医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Northeast YunNan Central Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国云南省昭通市昭阳区凤凰街道鲁甸路619号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 619 Ludian Road, Fenghuang Subdistrict, Zhaoyang District, Zhaotong, Yunnan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
本研究受到昆明医科大学恒瑞科研基金项目支持 |
||||||||||||||||||||||
|
Source(s) of funding: |
This study was supported by the Hengrui Research Fund of Kunming Medical University |
||||||||||||||||||||||
|
研究疾病: |
消化系统恶性肿瘤 |
||||||||||||||||||||||
|
Target disease: |
Digestive System Malignancies |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
1.了解消化系统恶性肿瘤患者核心症状影响因素,筛选生成最优指标集; 2.前瞻性研究收集消化系统恶性肿瘤患者核心症状的风险指标数据,分别构建RF-SVM预警模型、Logistic回归模型、BP神经网络模型; 3.追踪研究对象一年内是否发生核心症状,通过绘制受试者工作特征曲线,评价三种预警模型的预测能力。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To identify the influencing factors of core symptoms in patients with digestive system malignancies and to screen for an optimal indicator set. 2. To prospectively collect data on risk indicators for core symptoms in patients with digestive system malignancies, and to construct three prediction models: a Random Forest-Support Vector Machine (RF-SVM) early-warning model, a Logistic regression model, and a Back Propagation (BP) neural network model. 3. To track the occurrence of core symptoms in the study cohort over a one-year period and to evaluate the predictive performance of the three models by plotting receiver operating characteristic (ROC) curves. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
1.本研究未使用任何药物;2.本研究未向研究对象提供任何治疗方案。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
1.No medications were administered in this study. 2.No therapeutic interventions were provided to the participants in this study. |
||||||||||||||||||||||
|
纳入标准: |
1.依据中华医学会放射肿瘤学分会临床诊断分期标准,病理学检查确诊为消化系统恶性肿瘤; 2.年龄>=18 岁; 3.意识清楚,能够进行正常交流; 4.定期门诊复查(第 1 年每 1~3 个月一次,第 2 年每 2~6 个月一次),有完整的临床资料和随访资料。; 5.自愿参与。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Pathologically confirmed diagnosis of a malignant tumor of the digestive system, staged according to the clinical diagnostic staging criteria established by the Chinese Society for Radiation Oncology. 2.Aged 18 years or older. 3.Conscious and able to communicate normally. 4.Regular outpatient follow-up (every 1–3 months in the first year, and every 2–6 months in the second year) with complete clinical and follow-up data available. 5.Voluntary participation. |
||||||||||||||||||||||
|
排除标准: |
1.合并有其他类型恶性肿瘤。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Presence of concomitant malignancies other than the primary digestive system tumor under study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-02-04 00:00:00至 To 2028-01-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-02-04 00:00:00 至 To 2028-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Upon study completion, data will be shared via the ResMan platform (www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表;电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF; Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |